Vertex Pharmaceuticals (VRTX) Long-Term Debt Issuances (2009 - 2021)

Vertex Pharmaceuticals' Long-Term Debt Issuances history runs 10 years deep, the most recent figure standing at $10.0 million for Q4 2021.

• On a quarterly basis, Long-Term Debt Issuances rose 114.68% year-over-year to $10.0 million in Q4 2021; TTM through Sep 2022 was $10.0 million, a 42.06% decrease from a year earlier, with the FY2021 full-year figure at $22.6 million, up 69.92% from the prior year.
• Long-Term Debt Issuances rose to $10.0 million in Q4 2021 per VRTX's latest filing, from $1.0 million in the prior quarter.
• Across five years, Long-Term Debt Issuances topped out at $30.0 million in Q4 2017 and bottomed at $1.0 million in Q3 2021.
• The 5-year median for Long-Term Debt Issuances is $5.3 million (2017), against an average of $7.2 million.
• Across the five-year window, Long-Term Debt Issuances surged 1576.16% in 2017 and sank 73.78% in 2018, its largest moves.
• Year by year, Long-Term Debt Issuances stood at $30.0 million in 2017, then sank by 73.78% to $7.9 million in 2018, then increased by 14.52% to $9.0 million in 2019, then slumped by 48.23% to $4.7 million in 2020, then jumped by 114.68% to $10.0 million in 2021.
• Per Business Quant, the three latest VRTX Long-Term Debt Issuances figures stand at $10.0 million (Q4 2021), $1.0 million (Q3 2021), and $8.0 million (Q2 2021).